Sign in
Active, not recruitingPhase 3

Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France35 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
272 people, planned
Started
7 Apr 2022
Ended
7 Oct 2026
Type of study
Interventional
Record updated
27 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Age ≥ 18 years ≤ 80 years
  • Diagnosis of ITP whatever the duration of the disease (newly diagnosed or relapsed) according to the standard definition
  • Platelet count ≤ 20 x 109/L
  • Any cutaneous and/or any mucosal bleeding manifestations
  • Affiliated to a social security regime
  • Written consent from patient

Who cannot take part

  • Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants
  • Previous non-response to IVIg or DEX
  • Treatment with prednisone (1 mg/kg per day) for more than 3 days
  • Symptomatic COVID-19 disease
  • Ongoing viral infection (uncontrolled HIV, Viral hepatitis, herpes, varicella, zona)
  • Uncontrolled diabetes (Acido-cetosis)
  • Ongoing severe infection
  • Severe Renal insufficiency (DFG < 45 ml.min.1.73m2)
  • Severe Cardiac insufficiency (FEVG < 30 %)
  • Life-threatening bleeding defined as Intracranial hemorrhage and/or active organ bleeding (GI tract, urinary tract or menorrhagia with at least a 2 g/dl decrease of hemoglobin value from baseline)
  • Psychotic state not yet controlled by treatment
  • Inability or refusal to understand or refusal to sign the informed consent from study participation
  • Persons deprived of their liberty by judicial or administrative decision
  • Persons under legal protection (guardianship, curatorship)
  • Pregnant or breastfeeding woman or ineffective contraception
  • Ongoing anticoagulation treatment (Therapeutic Low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs))
  • Any contraindications to the prescribed Ig IV or prednisone patent medicine and to Neofordex®

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate the non-inferiority in term of short-term response of oral dexamethasone given at 40 mg on days 1 to 4 compared to IVIg given at 1g/kg on days 1 and 2 in combination with prednisone (1 mg/kg per day for 3 weeks) in adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX)
Record updated
27 May 2025